FDA Approves First Cholesterol Pill to Rival the Power of Expensive Injections

A New Weapon Against High Cholesterol — No Needle Required

For millions of Americans battling dangerously high cholesterol, a new option has arrived — and it comes in the form of a once-daily pill. The FDA approved enlicitide (Lipfendra) on July 16 as the first oral PCSK9 inhibitor for reducing LDL cholesterol alongside diet and exercise in adult patients with hypercholesterolemia, including those with heterozygous familial hypercholesterolemia. The drug was developed by Merck, and its approval marks a turning point in how doctors can treat one of the most common and dangerous conditions in the country.

The significance here is hard to overstate. Until now, PCSK9 inhibitors were primarily available through injections. As one cardiologist put it, "PCSK9 inhibitors are among our most potent LDL-lowering therapies, but until now they have primarily been available as injectable medications. Some patients may be hesitant to take an injectable medication, and others may face practical barriers that make injectable therapies more challenging." A pill changes that equation entirely.

How It Works — and How Well

Lipfendra is a novel macrocyclic peptide and is the first FDA-approved oral PCSK9 inhibitor shown to lower LDL-C, also known as bad cholesterol. PCSK9 is a protein that weakens the liver's ability to clear cholesterol from the bloodstream. By blocking it, enlicitide allows the liver to pull more LDL out of circulation — reducing the buildup of plaque in artery walls that can restrict blood flow and trigger heart attacks.

The clinical results are striking. In two randomized, double-blind, placebo-controlled trials, mean LDL-C changes from baseline to week 24 were -56% and -59% in the Lipfendra groups compared with placebo. In the larger trial, enlicitide also produced a 54% mean reduction in non-HDL cholesterol and a 50% reduction in apolipoprotein B from baseline — both markers closely tied to cardiovascular risk. Adherence in the trial was notably high: 97% of participants reported taking all, or nearly all, of their prescribed doses.

The Access Problem — and Why This Drug Could Solve It

The power of PCSK9 inhibitors has never really been in question. The problem has always been getting them into patients' hands. Injectable versions of these drugs can cost more than $500 a month, and despite being shown to reduce the risk of heart attacks by 20% among high-risk patients, only about 1% of the roughly 6 million eligible patients actually use them. The barriers — cost, inconvenience, and needle aversion — have kept a highly effective class of drugs largely out of reach.

Merck priced the once-daily tablet at $315 per month, well below existing injectables. That's still a meaningful expense, and insurance coverage criteria for PCSK9 inhibitors — typically requiring a qualifying diagnosis, documented statin trial, and LDL above goal — have been loosening in 2026 but still require prior authorization from virtually every major payer, and formulary placement for Lipfendra has not yet been announced. So while the price drop is real, broader access will depend heavily on how insurers respond in the coming months.

What Comes Next

Enlicitide is designed to be used alongside statins, the widely prescribed pills that directly target cholesterol production. It isn't a replacement for those drugs — it's an add-on for patients who aren't hitting their LDL targets despite already being on standard therapy. The larger Phase 3 trial enrolled nearly 2,900 patients who had a history of a major cardiovascular event or elevated risk, all of whom required additional LDL reduction despite stable treatment with moderate- or high-intensity statins.

Over one in ten Americans age 20 and older have high cholesterol, and a vast number of them remain inadequately treated. A new daily pill will give people with stubbornly high cholesterol a cheaper, needle-free way to drive their levels down. Whether Lipfendra becomes a true game-changer will ultimately rest on how quickly payers, physicians, and patients embrace it — but the science, and now the regulatory green light, are firmly in place.